BRCA1 and ovarian carcinoma: In the recent publication by Mirza et al. [48] niraparib maintenance therapy had activity in all patients with platinum sensitive recurrent ovarian cancer, however there was improved progression free survival in patients with germline BRCA1/2 mutations and without germline BRCA1/2 mutations but with HRD.